Trials / Completed
CompletedNCT00426283
A Study of Flovent in Patients With Eosinophilic Esophagitis
A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Marc Rothenberg, MD · Academic / Other
- Sex
- All
- Age
- 3 Years – 30 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the effects (both good and bad) of high dose swallowed fluticasone propionate (Flovent) in subjects with eosinophilic esophagitis (EoE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flovent | 1760 mcg daily |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2011-12-01
- Completion
- 2012-03-01
- First posted
- 2007-01-24
- Last updated
- 2020-10-19
- Results posted
- 2014-02-03
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00426283. Inclusion in this directory is not an endorsement.